ArticleAnnals of Saudi medicine
Impact of ileostomy creation on apixaban plasma concentrations: a retrospective case-series.
Article in Annals of Saudi medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApixaban is a direct-acting oral anticoagulant indicated for stroke and systemic embolism prevention in atrial fibrillation (AF) and for the treatment of venous thromboembolism (VTE). It is absorbed throughout the small intestine, with possible contribution from the distal ileum and ascending colon. The effect of ileostomy creation, which excludes the colon from the gastrointestinal tract, on apixaban plasma concentrations remains unclear.
objectivesTo evaluate the impact of ileostomy creation on apixaban plasma concentrations.
designRetrospective case series.
settingA single tertiary care center in Saudi Arabia. PATIENTS AND
methodsPatients receiving apixaban who had peak apixaban plasma concentrations measured following ileostomy creation between January 2021 and June 2025 were included. Patients were followed for at least three months and up to 12 months, or until ileostomy closure, discontinuation of apixaban, or death, whichever occurred first.
main outcome measuresPeak apixaban plasma concentrations, proportion of patients within the expected 5th-95th percentile range reported in Phase II and Phase III trials, the distribution of apixaban plasma concentrations below or above the median of the expected range, and clinical bleeding or thrombotic events. SAMPLE SIZE: Ten patients.
resultsApixaban was prescribed for VTE in six patients and AF in four. Eight patients (80%) had peak apixaban concentrations within the expected 5th-95th percentile range of apixaban concentrations; one patient was below the 5th percentile, and one was above the 95th percentile. Six patients had apixaban plasma peak concentrations below the median of the expected 5th-95th percentile range. Two patients experienced rectal bleeding, and no thrombotic events were observed.
conclusionsIn patients with an ileostomy, apixaban peak concentrations generally fall within the expected 5th-95th percentile range, though frequently below the median. Ileostomy may slightly affect apixaban absorption, but does not appear to result in underexposure. Standard apixaban dosing seems appropriate. LIMITATIONS: Small sample size, lack of control, and retrospective design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.